Dolby Laboratories DLB
58.56
1.00
1.74%
as of 25 Sep
- Market cap
- $5.4B
- P/E
- 24.6×
Follow DLB
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
9.96% | 9.40% | 9.35% | 8.69% | |
| 8.05% | 7.57% | 7.52% | 7.12% | ||
ROIC |
9.01% | 8.24% | 8.08% | 8.06% | |
Return on Tangible Assets |
17.95% | 16.80% | 17.38% | 16.52% | |
Average Days of Receivables |
89.58 | 101.71 | 104.64 | 76.85 | |
Free Cash Flow per Share |
4.49 | 4.05 | 2.78 | 3.83 | |
Free Cash Flow |
430.26 | 386.30 | 264.72 | 361.13 | |
Capital Expenditures |
(41.94) | (33.92) | (73.11) | (76.47) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
13.78% | 12.61% | 10.23% | 13.13% | |
Accounts Receivable Turnover |
4.17 | 3.76 | 3.87 | 4.65 | |
Accounts Payable Turnover |
9.09 | 16.08 | 9.03 | 11.30 | |
Inventory Turnover |
4.99 | 5.15 | 5.15 | 5.31 | |
Average Days of Payables |
40.66 | 19.46 | 44.04 | 27.13 | |
Days of Inventory on Hand |
69.35 | 70.20 | 67.97 | 66.94 | |
Tax Rate |
(0.15) | (0.16) | (0.15) | (0.18) | |
Research and Development Expense of Revenue |
19.40% | 19.74% | 19.50% | 19.64% | |
Selling, General and Administrative Expense of Revenue |
47.97% | 48.14% | 48.11% | 48.64% | |
Share Based Compensation of Revenue |
9.53% | 9.68% | 9.50% | 9.59% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.85 | 1.75 | 1.39 | 1.93 | |
Depreciation/Fixed assets |
0.21 | 0.21 | 0.22 | 0.23 | |
Capex/Depreciation |
(0.43) | (0.34) | (0.71) | (0.74) | |
Revenue per Share |
14.07 | 14.02 | 14.33 | 14.37 | |
Operating CF per Share |
4.93 | 4.40 | 3.55 | 4.64 | |
Capex per Share |
(0.44) | (0.36) | (0.77) | (0.81) | |
Capex to Sales |
0.03 | 0.03 | 0.05 | 0.06 | |
Net Profit Margin |
18.90% | 17.97% | 17.85% | 16.70% |
Columns are period end dates